Treatment of chorea associated with Huntington's disease: Focus on tetrabenazine

Consultant Pharmacist

Volumn 24, Issue 7, 2009, Pages 524-537

  Setter, Stephen M ^a   Neumiller, Joshua J ^a   Dobbins, Erin K ^b,c   Wood, Lindy ^a   Clark, Jeffrey ^a   DuVall, Cristina A K ^d   Santiago, Anthony ^a,e  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Family Home Care and Hospice of Spokane ^*  (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

^d Washington State Pharmacy Association   (United States)

^e Edward Ewell Parkinson's Disease and Movement Disorders Center   (United States)

Author keywords

Chorea; Huntington's disease; Tetrabenazine

Indexed keywords

AMIODARONE; CHLORPROMAZINE; CISAPRIDE; DISOPYRAMIDE; DOFETILIDE; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; FLUOXETINE; HALOPERIDOL; HUNTINGTIN; IBUTILIDE; LAPATINIB; LEVOFLOXACIN; METHADONE; MOXIFLOXACIN; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; PIMOZIDE; PLACEBO; PROCAINAMIDE; QUINIDINE; RANOLAZINE; RESERPINE; RISPERIDONE; SOTALOL; SUNITINIB; TETRABENAZINE; UNINDEXED DRUG;

ADL DISABILITY; AKATHISIA; ANXIETY; APPETITE; ATHETOSIS; BALANCE IMPAIRMENT; BRONCHITIS; CHOREA MINOR; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; DYSARTHRIA; DYSKINESIA; DYSPHAGIA; DYSPNEA; DYSTONIA; DYSURIA; ECCHYMOSIS; EXTRAPYRAMIDAL SYMPTOM; FALLING; FATIGUE; GAIT DISORDER; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUNTINGTON CHOREA; HYPERSALIVATION; INSOMNIA; IRRITABILITY; LACERATION; MAXIMUM PLASMA CONCENTRATION; MOTOR DYSFUNCTION; NAUSEA; OBSESSION; PARKINSONISM; PATHOGENESIS; PHARMACIST; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; REVIEW; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TARDIVE DYSKINESIA; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINE INCONTINENCE; VOMITING; WEAKNESS;

ADRENERGIC UPTAKE INHIBITORS; CHOREA; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; HUNTINGTON DISEASE; PATIENT EDUCATION AS TOPIC; TETRABENAZINE;

EID: 67650936053     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2009.524     Document Type: Review

References (57)

1. Huntington G. On chorea. The Medical and Surgical Reporter 1872;XXVI:320-321
2. Squitieri F, Gellera C, Canella M. Homozygosity for CAG mutation in Huntington disease associated with a more severe clinical course. Brain 2003;126:946-955 (Pubitemid 36372991)
3. Kremer B, Goldberg P, Andrew SE. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994;330:1401-1406 (Pubitemid 24984698)
4. Nance MA. US Huntington Disease Genetic Testing Group. Genetic testing of children at risk for Huntington's disease. Neurology 1997;49:1048-1053
5. Li H, Li SH, Johnston H et al. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet 2000;25:385-389 (Pubitemid 32983427)
6. Wong HK, Bauer PO, Kurosawa M et al. Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via ubiquitin-proteasome system-dependent mechanism. Hum Mol Genet 2008;20:3223-3235
7. Paoletti P, Vila I, Rife M et al. Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J Neurosci 2008;40:10090-10101
8. Estrada Sánchez AM, Mejía-Toiber J, Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 2008;39:265-276 (Pubitemid 351221151)
9. Thieben MJ, Duggins AJ, Good CD. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002;125:1818-1828 (Pubitemid 34885709)
10. Rosas HD, Koroshetz WJ, Chen YI. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003;60:1615-1620 (Pubitemid 36618087)
11. Ciarmiello A, Cannella M, Lastoria S et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 2006;47:215-222 (Pubitemid 46780885)
12. Politis M, Pavese N, Tai YF et al. Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain 2008 (epub ahead of print - October 1).
13. Fahn SF, Jankovic J. Huntington disease. In: Principles and Practice of Movement Disorders. Philadelphia, PA: Churchill Livingstone Elsevier; 2007:369-392
14. Purdon SE, Mohr E, Hivitsky V et al. Huntington's disease: pathogenesis, diagnosis and treatment. J Psychiatr Neurosci 1994;19:359-367 (Pubitemid 24352711)
15. Kirkwood SC, Su JL, Conneally PM et al. Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol 2001;58:273-278 (Pubitemid 32163165)
16. Mahant N, McCusker EA, Byth K et al, Huntington Study Group. Huntington's disease: clinical correlates of disability and progression. Neurology 2003;61:1085-1092
17. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;11:136-142 (Pubitemid 26082779)
18. Pavese N, Andrews TC, Brooks DJ. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 2003;126:1127-1135 (Pubitemid 36522955)
19. Craufurd D, Thompson JC, Snowden JS. Behavioral changes in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:219-226
20. Wheelock VL, Tempkin T, Marder K et al. Predictors of nursing home placement in Huntington disease. Neurology 2003;60:998-1001. (Pubitemid 36348935)
21. Folstein SE, Folstein MF. Psychiatric features of Huntington's disease: recent approaches and findings. Psychiatr Dev 1983;1:193-205.
22. Farrer LA. Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet 1986;24:305-311 (Pubitemid 16086550)
23. Bird TD. Outrageous fortune: the risk of suicide in genetic testing for Huntington disease. Am J Hum Genet 1999;64:1289-1292 (Pubitemid 30468746)
24. Sørensen SA, Fenger K. Causes of death in patients with Huntington's disease and in unaffected first degree relatives. J Med Genet 1992;29:911-914 (Pubitemid 23035219)
25. Lawrence AD, Sahakian BJ, Hodges JR et al. Executive and mneumonic functions in early Huntington's disease. Brain 1996;119:1633-1645 (Pubitemid 26375733)
26. Hunt VP, Walker FO. Dysphagia in Huntington's disease. J Neurosci Nur 1989;21:92-95
27. Leopold NA, Kagel MC. Dysphagia in Huntington's disease. Arch Neurol 1985;42:57-60.
28. Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006;12:2701-2720
29. Xenazine [package insert]. Washington, DC: Prestwick Pharmaceuticals; May 2008.
30. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006;6:7-17.
31. Frank S, Ondo W, Fahn S et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008;31:127-133 (Pubitemid 351787108)
32. Mehavar R, Jamili F, Watson MW et al. Pharmacokinetics of tetrabenazine and its major metabolite in man and rate. Bioavailability and dose dependency studies. Drug Met Disp 1987;15:250-255
33. Ondo WG, Tintner R, Thomas M et al. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol 2002;25:300-302 (Pubitemid 36025267)
34. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372
35. Chatterjee A, Frucht SJ. Tetrabenazine in the treatment of severe pediatric chorea. Mov Disord 2003;18:703-706 (Pubitemid 36790289)
36. Hawkes CH, Nourse CH. Tetrabenazine in Sydenham's chorea. Br Med J 1977;1:1391-1392
37. Heggarty H, Wright T. Tetrabenazine in athetoid cerebral palsy. Develop Med Child Neurol 1974;16:137-142
38. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, ties, and other dyskinesias. Neurology 1988;38:391-394 (Pubitemid 18083674)
39. Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology 1981;31:1051-1054
40. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982;11:41-47 (Pubitemid 12209517)
41. Pakkenberg H, Fog R. Spontaneous oral dyskinesia: results of treatment with tetrabenazine, pimozide, or both. Arch Neurol 1974;31:352-353
42. Kazamatsuri H, Chien CP, Cole JO. Treatment of tardive dyskinesia: I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 1972;27:95-99
43. Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 1973;130:479-483
44. Godwin-Austen RB, Clark T. Persistent phenothiazine dyskinesia treated with tetrabenazine. Br Med J 1971;4:25-26
45. Sweet RD, Bruun R, Shapiro E et al. Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Arch Gen Psychiatry 1974;31:857-861
46. Lang AE, Marsden CD. Alphamethylparatyrosine and tetrabenazine in movement disorders. Clin Neuropharmacol 1982;5:375-387
47. Jankovic J, Ford J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 1983;13:402-411
48. Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv Neurol 1983;225:515-521
49. Rascol O, Fabre N. Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin Neuropharm 2001;24:313-323
50. Prestwick Pharmaceuticals. Tetrabenazine: briefing document for peripheral and central nervous system advisory committee. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4328b1-02-Prestwick.pdf. Accessed September 9, 2008.
51. Micromedex Healthcare Series. Thomson Micromedex Online. Available at http:www.thomsonhc.com. Accessed October 10, 2008.
52. Petzinger GM, Bressman SB. A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment. Mov Disord 1997;12:246-248 (Pubitemid 27152033)
53. Ossemann M, Sindic CJM, Laterre C.Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov Disord 1996;11:95.
54. Burke RE, Fahn S, Mayeux R et al. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology 1981;31:1022-1026 (Pubitemid 11061744)
55. Mateo D, Munoz-Blanco JL, Gimenez-Roldan S. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clin Neuropharmacol 1992;15:63-68
56. Clinical Pharmacology Online. Available at http://clinicalpharmacology. com. Accessed October 10, 2008.
57. Lexi-Comp Online. Available at http://online.lexi.com. Accessed October 10, 2008.